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Original article

An Investigation of the Behavioral Mechanisms of Antipsychotic
Action Using a Drug-Drug Conditioning Paradigm
Ming Li (mli2@unl.edu), Wei He and Alexa Mead
Antipsychotic drugs at noncataleptic doses selectively suppress conditioned avoidance response in rats. In our previous
study, we had used a two-way active avoidance response paradigm to show that the antipsychotic-induced interoceptive
state is one of the mechanisms underlying the avoidance-disruptive effect of antipsychotics. In this study, we sought to
further examine this mechanism using a novel drug-drug conditioning procedure. We made use of the fact that both
the typical neuroleptic haloperidol and the atypical neuroleptic olanzapine disrupt conditioned avoidance responding,
whereas chlordiazepoxide (an anxiolytic) does not. We reasoned that if the antipsychotic interoceptive state is important
in causing a disruption on avoidance responding (an index of antipsychotic efficacy), pairing chlordiazepoxide (a cueing
drug conditional stimulus) with haloperidol or olanzapine (a cued drug unconditional stimulus) should engender
chlordiazepoxide to exhibit this property and behave like an antipsychotic drug. Chlordiazepoxide exhibited an acquired
antipsychotic-like property in disrupting avoidance responding after being repeatedly paired with haloperidol, but not
with olanzapine. In contrast, it significantly attenuated the antiavoidance efficacy of olanzapine but not haloperidol
after being repeatedly paired with these drugs. This study suggests that the haloperidol-induced interoceptive drug
state is directly involved in its antiavoidance action, and chlordiazepoxide may attenuate the antiavoidance efficacy of
antipsychotics (especially olanzapine). To the extent that the antiavoidance effect predicts clinical effects of antipsychotic
treatment, this study suggests that the antipsychotic-induced interoceptive drug state may be an important behavioral
mechanism mediating the clinical effects of antipsychotic treatments.
Keywords: antipsychotic drugs, chlordiazepoxide, conditioned avoidance response, drug-drug conditioning, polypharmacy, psychotherapeutic
drug-drug interaction, rat, schizophrenia
Received October 31,2008; accepted as revised February 17, 2009.

Introduction
Antipsychotic drugs (APDs) are effective in the treatment of positive symptoms of schizophrenia (Lieberman
et al., 2005). Research over the years has shown that actions at various receptor sites, notably dopamine D2, serotonin 5-HT2A, and 5-HT1A receptors, are critically important for the therapeutic effect of both typical and atypical
drugs (Seeman, 2000; Kapur and Mamo, 2003; Richtand
et al., 2007). It is still not well understood how this action
at the neurobiological level translates into symptom improvement. This situation is peculiar given the fact that
schizophrenia is a cluster of psychological symptoms, and
the diagnosis and symptom improvement all manifests at
the psychological level. The neurobiological level of explanations of antipsychotic action alone is clearly insufficient to account for the clinical effect of antipsychotic action (Miller, 1987; Kapur, 2003). To understand fully how
antipsychotics work, a detailed understanding of the behavioral mechanisms of antipsychotic action is needed.

We recently took a preclinical approach and investigated this issue using a well-established preclinical animal model of antipsychotics-conditioned avoidance response (CAR) model (Li et al., 2007, 2009; Mead and Li,
in press). All currently available antipsychotics, at clinically relevant doses, selectively disrupt avoidance responding to a conditional stimulus (CS, e.g. white noise)
without altering escape responding to an unconditional
stimulus (US, e.g. footshock) (Arnt, 1982; Wadenberg et
al., 2001; Natesan et al., 2006). Thus, an antiavoidance responding effect is frequently used as a validated behavioral index of ‘antipsychotic’ property. Using this model,
we found that rats treated with haloperidol (HAL), risperidone (RIS) and olanzapine (OLZ) daily for 7 consecutive days showed a progressive across-session decline
in avoidance responding, suggesting that antipsychotics may progressively attenuate the motivational salience
of the CS (Wise, 2004; Li et al., 2009). We also found that
rats previously treated with HAL and OLZ, and retested
under the same dose of drugs after their avoidances re-
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covered to the predrug level, showed fewer avoidances
than when they were first tested (Mead and Li, in press).
This finding indicates that the interoceptive drug state induced by HAL may also play a role in causing a progressive decline in avoidance across sessions. On the basis of
these findings, we proposed that antipsychotics may suppress avoidance responding through a dual action: (i) decreasing the motivational salience of stimuli; (ii) providing an interoceptive drug cue that allows the decreased
salience of stimuli to be maintained over time.
In contrast to the well-documented salience attenuation
effect of antipsychotics (Fouriezos et al., 1978; Berridge
and Robinson, 1998; Dickinson et al., 2000; Wise, 2004;
Colpaert et al., 2007), the notion that the drug-induced interoceptive state(s) may be involved in the antipsychotic
effects is relatively new, although preclinical studies such
as those based on drug discrimination and state-dependent learning have long recognized the distinct drug states
induced by typical and atypical antipsychotics (Overton,
1979; Goudie et al., 1998; Porter et al., 2000b; Porter et al.,
2005). The primary goal of this study was thus to examine this mechanism further, using a novel drug-drug conditioning paradigm in the CAR model. In this study, we
utilized the fact that both HAL (typical APD) and OLZ
(atypical APD) disrupt conditioned avoidance responding, whereas chlordiazepoxide (CDP) does not (Sanger,
1985; Li et al., 2004, 2007). If the antipsychotic-induced
state is directly involved and critically important in causing a disruption on avoidance responding, pairing CDP
with HAL or OLZ through a drug-drug conditioning procedure (Revusky et al., 1989; Taukulis, 1996) should alter
the intrinsic property of CDP and engender it to show a
disruptive effect on avoidance responding. In Pavlovian
terminology, the CDP was considered a CS drug, which
signals to an organism that the effects of HAL or OLZ
(US) are imminent. Any avoidance-disruptive effect exhibited by CDP after repeated pairing with HAL or OLZ
would support the notion that antipsychotic-induced interoceptive state is ‘directly’ involved in the antipsychotic
effect.
As psychotic fear and anxiety disturbances are seen at
a relatively high frequency in patients with schizophrenia (Siris, 1994), anxiolytic drugs are frequently combined
with antipsychotics in schizophrenic patients (ZumBrunnen and Jann, 1998). This practice of psychotropic polypharmacy has raised some concerns regarding the possible
adverse effects of drug-drug interactions (Sandson et al.,
2005). This study also allowed us to examine how the repeated pairings of CDP with HAL and OLZ might alter
the intrinsic drug efficacy of HAL and OLZ.

Methods
Subjects
Male Sprague-Dawley rats (226-250 g upon arrival,
Charles River, Portage, Michigan, USA) were housed two
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per cage, in 48.3 × 6.7 × 20.3 cm transparent polycarbonate
cages under 12-h light/dark conditions (light on between
6:30 am and 6:30 pm). Room temperature was maintained
at 21 ± 11°C with a relative humidity of 55-60%. Food and
water was freely available. Animals were allowed at least
1 week of habituation to the animal facility before being
used in experiments. All procedures were approved by
the Institutional Animal Care and Use Committee at the
University of Nebraska-Lincoln.
Avoidance conditioning apparatus
Six identical two-way shuttle boxes, custom designed
and manufactured by Med Associates (St. Albans, Vermont, USA), were used. Each box was housed in a ventilated, sound-insulated isolation cubicle (96.52 cm wide ×
35.56 cm deep × 63.5 cm high). Each box was 64 cm long,
30 cm high (from grid floor) and 24 cm wide, and divided
into two equal-sized compartments by a white polyvinyl
chloride partition with an arch-style doorway (15 cm high
× 9 cm wide at base). An aluminum hurdle (4 cm high)
was placed between the two compartments, so the rats
had to jump from one compartment to enter the other.
The grid floor consisted of 40 stainless-steel rods, spaced
1.6 cm apart center to center, through which a scrambled footshock (0.8 mA) was delivered by a constant current shock generator (Model ENV-410B) and scrambler
(Model ENV-412). The location of the rat and motor activity were detected by a set of 16 photobeams (ENV-256-8P)
affixed at the bottom of the box (3.5 cm above the grid
floor). A speaker (ENV 224AMX) mounted on the ceiling
of the cubicle, centered above the shuttle box, was used
to provide a CS (76 dB white noise). All the training and
testing procedures were controlled by Med Associates
programs running on a computer. Background noise (approximately 74 dB) was provided by a ventilation fan affixed at the top corner of each isolation cubicle.
Drugs
The injection solutions of HAL (5 mg/ml ampoules, Sabex Inc., Boucheville, Quebec, Canada) and CDP (SigmaAldrich, St Louis, Missouri, USA) were obtained by mixing drugs with sterile water. OLZ (Toronto Research
Chemical Inc., Canada) was dissolved in 1.5% glacial acetic acid in distilled water. HAL and OLZ were administered s.c., whereas CDP was administered intraperitoneally. The doses of HAL (0.05 mg/kg) and OLZ (1.0 mg/
kg) and their injection route were chosen based on (i) our
previous work showing that at the chosen doses, HAL
and OLZ injected s.c. produce a comparable progressive
across-session decline in avoidance responding (Li et al.,
2007); and (ii) rat brain D2 receptor occupancy data showing that both drugs give rise to clinically comparable levels of D2 occupancy (65-80%) (Kapur et al., 2003). The
choice of CDP dose (10 mg/kg) and its route of injection
was based on the findings showing that (i) CDP (10 mg/
kg) is ineffective in disrupting avoidance responding (Li
et al., 2004, 2007); (ii) CDP at this dose is effective in several aversively conditioned paradigms, such as Pavlov-
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ian fear conditioning and passive avoidance responding
(Klint, 1991; Joordens et al., 1998); and (iii) at this dose, CDP
produces a powerful internal drug cue (Colpaert, 1986).
Experiment 1: effects of repeated chlordiazepoxide and
haloperidol pairing on avoidance responding to chlordiazepoxide and haloperidol
The experiment comprised of the following three
phases: avoidance training, drug–drug conditioning, and
drug testing.
Avoidance training phase
Forty-two rats were first handled and habituated to the
avoidance conditioning apparatus for 2 days (30 min/
day), and then trained for 10 consecutive days to acquire
robust conditioned avoidance responding (> 70% avoidance trials). Each training session consisted of 30 discrete
trials. Every trial was started by presenting white noise
(CS, 76 dB) for 10 s, followed by a continuous footshock
(US, 0.8 mA, maximum 5 s) on the grid floor. If a subject
moved from one compartment into the other within the
10 s of CS presentation, the shock was prevented, and this
shuttling response was recorded as ‘avoidance’ (a twoway avoidance). If the rat remained in the same compartment for more than 10 s and made a crossing upon receiving the footshock, this response was recorded as ‘escape.’
If the rat did not respond during the entire 5 s presentation of the shock, the trial was terminated and ‘escape
failure’ was recorded. Intertrial intervals varied randomly
between 30 and 60 s.
Drug conditioning phase
At the end of the training phase, rats (n = 32) that had
reached the training criterion (≥ 70% avoidance in each
of the last two sessions) were used in the drug conditioning phase. They were randomly assigned to one of four
groups. On day 1, each group was given a double injection of one of the following combinations: CDP + vehicle
(VEH) (n = 8), VEH + HAL (n = 7), CDP+HAL (n =7), and
VEH +VEH (n = 10). The first injection (CDP 10.0 mg/
kg, or sterile water, 1.0 ml/kg, i.p.) was given 15 min before the second injection (HAL 0.05 mg/kg, or sterile water, 1.0 ml/kg, s.c.). One hour after the second injection,
rats were placed in the avoidance conditioning boxes
and tested. This time interval between CDP and HAL (15
min) was determined so that there was sufficient time for
the drug effects of HAL and CDP to overlap and produce a robust drug-drug conditioning effect, given the
half-life of CDP at 4-6 h (Koechlin et al., 1965) and HAL
at about 1.5 h (Cheng and Paalzow, 1992). A similar kind
of drug-drug conditioning arrangement had been used
by Taukulis and Brake (1989). On day 2, rats in the CDP
+ VEH, VEH + HAL, and CDP + HAL groups received
a single injection of HAL, CDP, and VEH, respectively,
whereas the Behavioral mechanisms of antipsychotic action Li et al. 3 VEH + VEH group received a double injection of CDP and HAL separated by 15 min. Immediately after the injections, rats were returned to their home
cages. No avoidance test was done on this day. The pur-
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pose of giving rats the drug treatments on day 2 and not
testing them was to ensure that every rat received the
same drug treatment (all rats had CDP, HAL, and VEH),
although in different contexts (e.g. home cage vs. CAR
boxes) and with different drug injection intervals (15 min
vs. 24 h), so that the specific drug-drug conditioning effect on avoidance behavior could be assessed. On day 3,
all rats were untreated and unhandled. This 3-day drug
conditioning cycle repeated for seven times over a 21day period, after which all rats were re-trained drug-free
in two consecutive sessions to bring back a high level of
avoidance responding.
Drug-testing phase
The drug-testing phase started 24 h after the last retraining session. Rats were first injected with CDP (10.0 mg/
kg, i.p.) and tested 75 min later. The next day, rats were
retrained drug-free, and 1 day later, tested again under
HAL [0.05 mg/kg, subcutaneously (s.c.), – 60 min]. For
both drug tests, the same conditioned avoidance procedure was used except that only the CS was presented in
the 30 trials. No shock US was ever presented. The following figure illustrates the general experimental procedure (Figure 1).
Experiment 2: effects of repeated chlordiazepoxide and
olanzapine pairing on avoidance responding to chlordiazepoxide and olanzapine
This experiment was identical to experiment 1 except
that HAL was replaced by OLZ. Forty-two rats were used,
of which 30 reached learning criterion. They were then
randomly assigned to one of the following four groups:
CDP + VEH (n = 6), VEH + OLZ (n = 8), CDP+OLZ (n = 9),
and VEH + VEH (n = 7), and were subjected to the seven
sessions of drug conditioning and two sessions of drug
testing (the CDP test followed by the OLZ test).
Experiment 3: reexamining the effects of repeated
chlordiazepoxide and haloperidol pairing on avoidance
responding to chlordiazepoxide and haloperidol
As the CDP + HAL (experiment 1) and CDP + OLZ
pairing (experiment 2) produced different results, we reexamined the effects of repeated CDP and HAL pairing
on avoidance responding to CDP and HAL. Twenty rats
that had experienced the same white noise and footshock
in a Pavlovian fear-conditioning paradigm were used. It
should be noted that none of the rats were ever exposed
to any drug before this experiment and that there was at
least a 2-week window between the previous experiment
and this one (unpublished experiment). The basic procedure was the same as the one used in the previous two
experiments. First, all rats were trained in 10 avoidance
conditioning sessions. At the end of the training Figure
2 phase, 15 rats reached the learning criterion and were
randomly assigned to two groups: CDP + HAL (n = 8)
and VEH+HAL (n = 7). They were then subjected to the
seven sessions of drug conditioning and two sessions of
drug testing (the CDP test followed by the HAL test).
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Statistics
The main dependent variable was the number of avoidance responses (expressed as mean ± SEM). Data from
the drug-drug conditioning phase were first analyzed using a repeated-measures analysis of variance (ANOVA)
with treatments (i.e. four groups) as a between-subjects
CDP+VEH (n = 8)factor and the test sessions (i.e. seven
drug sessions) CDP + HAL (n = 7) VEH + VEH (n = 10)
VEH + HAL (n = 7) as a within-subjects factor, followed
by post-hoc Tukey’s honestly significant difference test
to detect the group differences. If a significant group difference was detected, one-way ANOVAs were then used
to specify the difference for each drug session. Data from
the drug-testing phase were analyzed separately using
one-way ANOVAs, followed by Tukey’s test. A conventional two-tailed level of significance at the 5% level was
required.

Results
Experiment 1: effects of repeated chlordiazepoxide and
haloperidol pairing on avoidance responding to chlordiazepoxide and haloperidol
Figure 2 shows the number of avoidance responses
made by the rats in the four groups during the seven

drug conditioning sessions and two drug-free retraining
sessions. The two HAL groups (e.g. the CDP + HAL and
VEH + HAL) showed a progressive across-session decrease in avoidance responding under drug and a quick
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recovery when the treatment was stopped. The other two
groups (e.g. the CDP + VEH and VEH + VEH) maintained
a high level of avoidance responding throughout the entire drug conditioning phase. For the seven drug conditioning sessions, a two-way ANOVA (‘treatments’ × ‘sessions’) showed a significant effect of ‘treatments’ [F(3,28) =
322.85, P < 0.001], ‘sessions’ [F(6,168) = 28.04, P < 0.001], and
a significant ‘treatments’ × ‘sessions’ interaction [F(18,168) =
15.173, P <0.001]. Post-hoc Tukey tests revealed that the
CDP + HAL and VEH + HAL groups were significantly
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different from the CDP + VEH and VEH + VEH groups
(all P values < 0.001). Interestingly, the CDP + HAL group
also differed significantly from the VEH + HAL group (P
= 0.045). Individual one-way ANOVA revealed that on
the first two drug conditioning days, the CDP + HAL rats
displayed higher numbers of avoidance responses than
the rats in the VEH + HAL group (day 1: P < 0.05; day
2: P < 0.05), indicating that CDP may have attenuated
the HAL effect, at least at the early stage of paired drug
treatment. This attenuation was also reflected in the two
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subsequent retraining sessions, as the CDP + HAL group
reinstated avoidance responding much faster than the
VEH + HAL group (CDP + HAL vs. VEH + HAL: day 1:
P < 0.01; day 2: P < 0.05). Furthermore, the CDP + HAL
group showed no significant difference when compared
with the CDP + VEH and VEH + VEH groups (all P values > 0.09), whereas the VEH + HAL did (all P values <
0.01).
Figure 3a shows the number of avoidance responses
during the CDP test. Both the CDP + VEH and VEH +
VEH groups exhibited a high level of avoidance responding (the average was 26.4 and 25.7 avoidances, respectively), as did the VEH + HAL group (mean number:
19.4), even though there was no shock (only white noise)
present during this test. This finding was consistent with
the data from the drug conditioning phase, showing that
CDP itself has no effect on avoidance responding. In contrast, the CDP + HAL group exhibited the lowest avoidance responses (8.1). One-way ANOVA revealed that the
CDP + HAL group was significantly different from the
other three groups (all P values < 0.025), strongly suggesting that CDP produced a significant inhibition of avoidance responding. In other words, CDP ‘acquires’ a HALlike property (e.g. disrupting avoidance responding) after
being repeatedly paired with HAL. Prior CDP + HAL
pairing in the absence of avoidance testing (e.g. the VEH
+ VEH group) did not change its property.
After a retraining session [pre-HAL session: no group
difference was detected, F(3,28) = 2.16, P = 0.12, Figure 3b],
all rats were tested for their avoidance responses under
HAL in a CS-only session (Figure 3b). In comparison
with the pre-HAL session, avoidance responding was apparently lower in all groups. A 4 × 2 repeated-measures
ANOVA (‘treatment’ × ‘sessions’) showed a significant
effect of ‘treatment’ [F(3,28) = 5.34, P < 0.005], ‘sessions’
[F(1,28) = 640.48, P < 0.001], and a significant ‘treatment’
× ‘sessions’ interaction [F(3,28) = 3.45, P < 0.05]. One-way
ANOVA focusing on the HAL test session revealed no
significant group difference except between the VEH +
HAL and VEH + VEH groups (P < 0.005), indicating a
strong HAL experience effect consistent with our previous finding (Li et al., 2007). More importantly, no significant group difference was detected between the VEH +
HAL and CDP + HAL groups, indicating that the efficacy
of HAL had not been altered even after being repeatedly
paired with CDP.
Experiment 2: effects of repeated chlordiazepoxide and
olanzapine pairing on avoidance responding to chlordiazepoxide and olanzapine
Figure 4 shows the number of avoidance responses
made by the rats in the four groups during the seven
drug conditioning sessions and two drug-free retraining
sessions. Similar to what was seen in experiment 1, the
two OLZ-treated groups (e.g. the CDP + OLZ and VEH
+ OLZ) showed a progressive across-session decrease in

a

D rug -D rug C onditioning P aradigm

189

avoidance responding under drug and a quick recovery
when OLZ treatment was stopped. The other two groups
(e.g. the CDP + VEH and VEH + VEH) maintained a high
level of avoidance responding throughout the entire drug
conditioning phase. For the seven drug conditioning
sessions, a two-way ANOVA (‘treatments’ × ‘sessions’)
showed a significant effect of ‘treatments’ [F(3,26) = 69.05, P
< 0.001], ‘sessions’ [F(6,156) = 6.91, P < 0.001], and a significant ‘treatments’ × ‘sessions’ interaction [F(18,156) = 4.29, P
< 0.001]. Post-hoc two-group comparisons revealed that
both OLZ-treated groups were significantly different
from the other two groups (all P values < 0.001), indicating a potentiated inhibitory effect of repeated OLZ treatment on avoidance responding. This potentiated effect
appears to be attenuated to an extent by CDP, as the CDP
+ OLZ group showed less of a decrease than the VEH +
OLZ group. Independent samples t-tests on each drug
conditioning day revealed that there were significant differences between the two groups on day 4(P < 0.001), day
5 (P < 0.02), and day 6 (P < 0.05).
Figure 5a shows the number of avoidance responses during the CDP test. All four groups showed a comparably
high level of avoidance responding. One-way ANOVA
did not show any significant group difference [F(3,26) = 1.97,
NS], suggesting that CDP given alone or in combination
with OLZ did not change its action on avoidance behavior. After a retraining session [pre-OLZ session: no group
difference was detected, F(3,26) = 2.77, P = 0.061, Figure 5b],

190							

all rats were tested for their avoidance responses under
OLZ in a CS-only session. In comparison with the preOLZ session, avoidance responses were significantly decreased by OLZ, especially in the CDP + VEH and VEH
+ OLZ groups. A 4 × 2 two-way ANOVA (‘treatment’ ×
‘sessions’) showed a significant effect of ‘treatment’ [F(3,26)
= 8.11, P < 0.001], ‘sessions’ [F(1,26) = 149.25, P < 0.001], and
a significant ‘treatment’ × ‘sessions’ interaction [F(3,26) =
5.04, P < 0.01]. Post-hoc two-group comparisons revealed
that the CDP + OLZ and VEH + VEH groups were significantly different from the CDP + VEH and VEH + OLZ
groups (all P values < 0.05). The CDP + VEH group did
not differ from the VEH + OLZ group. As the CDP +
OLZ and VEH + VEH groups all received a double drug
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treatment (e.g. CDP and OLZ pairing), this result suggests
that OLZ might lose its antipsychotic action after being
repeatedly paired with CDP.
Experiment 3: reexamining the effects of repeated
chlordiazepoxide and haloperidol pairing on avoidance
responding to chlordiazepoxide and haloperidol
Figure 6 shows the number of avoidance responses
during the seven drug conditioning sessions and two
drug-free retraining sessions. Both groups showed a
progressive across-session decrease in avoidance responding under drug, and a recovery when HAL was
stopped. For the seven drug conditioning sessions, a
two-way ANOVA (‘treatments’ × ‘sessions’) showed a
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significant effect of ‘sessions’ [F(6,78) = 6.36, P < 0.001], but
not ‘treatments’ [F(1,13) = 0.048, NS], or ‘treatments’ × ‘sessions’ interaction [F(6,78) = 0.806, NS]. During the two subsequent retraining sessions, it appeared that the CDP +
HAL group reinstated avoidance behavior much faster
than the VEH + HAL group and had higher mean numbers of avoidances on both days. This group difference
was significant on the first day (P < 0.05), but failed to
reach a significant level on the second day.
The pattern was reversed on the CDP test (Figure 7a).
The CDP + HAL group showed many fewer avoidances
than the VEH + HAL group, and this difference was statistically significant [t(13) = 3.00, P < 0.01]. This result confirmed the finding from experiment 1 and supported the
notion that CDP might ‘acquire’ an antipsychotic property after being repeatedly paired with HAL.
After a retraining session [pre-HAL session: no group
difference was detected, t(13) = – 1.82, NS, Figure 7b], all
rats were tested for their avoidance responses under HAL
in a CS-only session (Figure 7b). As can be seen in Figure
7b, in comparison with the pre-HAL session, avoidance
responding was significantly decreased by HAL [F(1,13) =
173.26, P < 0.001]. There was no significant difference between groups [F(1,13) = 2.49, NS], indicating that the efficacy of HAL was not altered even if it had been repeatedly paired with CDP.

Discussion
In the three experiments, we used a novel drug–drug
conditioning paradigm and examined the role of anti-

psychotic-induced interoceptive state in the therapeutic effects of antipsychotic treatment. Results from experiments 1 and 3 suggest that the HAL-induced interoceptive state may be involved in its disruptive effect on
avoidance responding, as evidenced by the finding showing that CDP + HAL pairing produced an anti-avoidance (e.g. antipsychotic-like) drug activity in CDP. This
‘acquired’ HAL activity of CDP is attributed to specific
drug-drug conditioning with CDP functioning as the
drug CS, and HAL as the drug US (Taukulis and Brake,
1989). It is not simply because of pharmacological effects
of the drugs, as no such effect was found in two control
groups (the CDP + VEH and VEH + HAL), even though
they received the same numbers of CDP and HAL injections separated by 24 h. We also showed that, to induce
the anti-avoidance effect in CDP, CDP + HAL pairing had
to occur within the context of avoidance testing. The same
pairing in the home cage (the VEH + VEH group) did not
change the drug activity of CDP, indicating an important
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interaction between drug treatment and targeted behavior as well as the direct involvement of HAL-induced
drug state in the disruption of avoidance responding.
Unexpectedly, we did not find the same effect with CDP
+ OLZ pairing from experiment 2. CDP + OLZ pairing
did not change the drug activity of CDP on avoidance responding. However, it did change the efficacy of OLZ,
making it less effective in disrupting avoidance behavior
when it was tested alone. This effect is because of drugdrug conditioning, as the control groups without conditioning (the CDP + VEH and VEH + OLZ) did not show
such an effect. In addition, the contexts within which the
CDP + OLZ conditioning occurred were not critical because even the drug pairing in the home cage achieved a
similar effect (Figure 5b). Overall, the present findings reveal an interesting ‘double dissociation’ between the effect of CDP pairing with typical antipsychotic HAL and
atypical OLZ. CDP + HAL pairing changed the drug activity of CDP, but did not change that of HAL. CDP exhibited an acquired antiavoidance effect after being repeatedly paired with HAL. In contrast, CDP + OLZ pairing
changed the drug activity of OLZ, but not that of CDP.
OLZ became less effective in disrupting avoidance behavior after repeated pairing.
This study provides additional evidence showing that
the HAL-induced interoceptive state is related to its antiavoidance effect, a finding consistent with our previous
work (Li et al., 2007; Mead and Li, in press). The differential effect of CDP + HAL and CDP + OLZ pairing is
surprising, given the fact that both HAL and OLZ are
equally efficacious in the treatment of psychosis (Lieberman et al., 2003) and share a similar molecular mechanism in blocking dopamine D2 receptors (Kapur and Seeman, 2000). At the chosen doses, they also produced a
comparable level of avoidance disrupting effect over the
seven drug conditioning days (Figs 2 and 4). One possible explanation for the differential effect of CDP + HAL
and CDP + OLZ pairing is that HAL and OLZ may induce different interoceptive states that are differently influenced by CDP. Pharmacologically, HAL is primarily a
D2 receptor antagonist (Kapur et al., 1996), and it binds
‘tightly’ to the D2 receptor and dissociates slowly (Kapur
and Seeman, 2001), whereas OLZ has a moderate antagonist effect on the D2 receptor but a high antagonist effect on the 5-HT2A serotoninergic, α1 adrenergic, m1 muscarinic, and H1 histaminic receptors (Bymaster et al., 1999;
Miyamoto et al., 2005) (Table 1). It is possible that the
OLZ state is a compound cue that is mediated by its antagonism against multiple receptors (e.g. D2, 5-HT2A, α1,
m1 and H1, etc.), whereas the HAL state is a single cue
that is primarily mediated by antagonism against D2 receptors. Drug discrimination studies seem to support
this notion (Goudie and Taylor, 1998; Porter et al., 2000a;
Cole et al., 2007; Goudie et al., 2007). Using a two-lever
drug discrimination paradigm, Porter et al. (2000a) found
that the dopamine D2 antagonists chlorpromazine and

thioridazine substituted for OLZ in producing OLZ-appropriate responding in rats, as did the muscarinic cholinergic antagonist scopolamine and the 5-HT2A/2C serotonergic antagonist ritanserin. This finding suggests that
the antagonism of either dopamine D2 receptors, muscarinic receptors, or 5-HT2A/2C receptors is sufficient to
mimic the OLZ-induced interoceptive state. Colpaert et
al. (2007) used a two-lever, food-rewarded drug discrimination paradigm and found that HAL was more efficacious than OLZ in inducing ‘win-shift’ response pattern,
possibly because of its strong D2 receptor antagonism. As
the ‘antipsychotic’ action, as well as the antiavoidance
effect is thought to be mediated by antagonism against
D2 receptors (Wadenberg et al., 2001; Seeman, 2006), the
compound cue mediated by multiple receptor actions of
OLZ is apparently less effective in bestowing an antipsychotic property to CDP than the single cue mediated by
D2 blockade by HAL. This is because other discriminative
cues within this compound cue may obscure the ‘antipsychotic’ cue. Within the same line of reasoning, it is also
possible that the differential effects of CDP + HAL and
CDP + OLZ pairing is because of the differences between
the dopamine D2 receptor bindings of HAL and OLZ. The
binding affinity of HAL at D2 receptors is six to seven times
greater than that of OLZ (Richelson and Souder, 2000), so
although they may share a similar molecular mechanism
in blocking D2 receptors, they are not equally efficacious
at this site. This distinct molecular binding profile of OLZ
opens up the possibility that the discrepant findings represent a pharmacological effect between CDP and OLZ
that was not present between CDP and HAL.
Another unexpected finding is that repeated concurrent CDP and OLZ treatment attenuated the antiavoidance effect of OLZ (Figure 5b), but not HAL (Figure 3b
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and Figure 7b) in the drug-alone testing, implying that
the antipsychotic efficacy of OLZ, but not HAL, could be
potentially attenuated by CDP in the clinic. One clinical
report (Wolkowitz et al., 1989) and one preclinical report
(Keller et al., 1976) seem to suggest that benzodiazepines
may augment the drug effects of typical antipsychotics
during the combined drug treatment. Our results did not
show such an effect. Owing to limited research on this issue, it is premature to draw a definite conclusion. Future
work with more vigorous controls and a wide selection
of different types of benzodiazepines and antipsychotics
is needed.
Besides its contribution to understanding the behavioral mechanisms of antipsychotics, this study is important because it also provides an approach to study drug–
drug interactions in the treatment of schizophrenia. Most
schizophrenic patients are treated with multiple psychotherapeutic drugs, such as antipsychotics, selective serotonin reuptake inhibitors, and benzodiazepines to control
their diverse symptoms and comorbid anxiety and depression (ZumBrunnen and Jann, 1998). One recent report
found that concurrent prescriptions for anxiolytic medications with antipsychotics grew by more than two-thirds
from 1995 to 1999 in the state of New Hampshire (Clark
et al., 2002). This practice of psychotropic polypharmacy
has raised some concerns regarding the efficacy, costs,
and possible adverse effects of drug–drug interactions
(Alfaro, 2001; Sandson et al., 2005; Rupnow et al., 2007).
However, because current clinical data come mostly from
case reports and limited uncontrolled studies, it is difficult to assess the extent and nature of drug-drug interactions in schizophrenia (ZumBrunnen and Jann, 1998) and
determine their advantages or disadvantages. Our findings that the antiavoidance efficacy of HAL is actually attenuated by CDP during the early treatment phase (experiment 1, although not confirmed in experiment 3) and
the long-term antiavoidance efficacy of OLZ is also attenuated by CDP seem to suggest that cautions need to be
taken in monitoring the clinical responses of patients during the early stage of combined drug treatment and when
benzodiazepines are discontinued.
This present study is also important because it extends
research utilizing a Pavlovian Drug-drug conditioning
paradigm in the following two directions. First, it introduces a new behavioral model to assess associative conditioning involving two drug cues. In many drug conditioning studies, conditional responses are usually some
basic physiological or simple reactive behaviors, such as
drug-induced thermic effects, heart rate, stomach emptying, muscle relaxation, or taste aversions (Wilkin et al.,
1982; Revusky et al., 1989; Davey and Biederman, 1991;
Reilly and Revusky, 1992; Biederman and Davey, 1993).
This study shows that even instrumental conditioned active motor behavior can be used as a valid index to evaluate the conditioned drug effect. Second, it introduces a
new approach to examine the effects of drug-drug condi-
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tioning. In many drug conditioning studies, the drug conditioning effect is often indexed by some change in one
or more of the properties of the CS drug (Taukulis, 1996).
For example, in a series of studies on the diazepam-HAL
or diazepam-chlorpromazine conditioning (Taukulis and
Brake, 1989; Taukulis et al., 1992), the drug conditioning
was evidenced by the changed drug properties of diazepam, such as enhanced hypothermia, diminished muscle relaxation, and enhanced anxiolytic effect. As rightly
pointed out by Taukulis (1996), this approach occasionally
posits a challenge in the explanation for the drug conditioning phenomenon, because the specific unconditional
effects of the ‘signaled’ drug (drug US) have not always
been specified in advance. In this study, the conditioning effect was seen in the newly ‘acquired’ antipsychotic
property in CDP, which is not an intrinsic drug property
of CDP, and can only be attributed to the unconditioned
effect of HAL. This approach provides an unequivocal
demonstration of the drug-drug conditioning effect.
In summary, our results show that the HAL-induced interoceptive state is an important behavioral mechanism
responsible for the maintenance of its antiavoidance effect and possibly antipsychotic effect over time. Concurrent use of CPD with antipsychotics, especially with OLZ,
may cause a long-term attenuation of the antiavoidance
effect of OLZ through a drug-drug interaction mechanism. The model introduced in this study may be useful
in delineating behavioral mechanisms of antipsychotic
action and assessing polypharmacy involving drug-drug
conditioning in the treatment of schizophrenia.
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